Stock Updates

Is this Large Market Cap Stock target price reasonable for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)?

The company in question is, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) currently with a stock price of 63.07 (-4.70% today). The market cap for Ultragenyx Pharmaceutical Inc. is 2569.77, and is in the sector Healthcare, and Biotechnology industry. The target price for Ultragenyx Pharmaceutical Inc. is 96.5. Currently Ultragenyx Pharmaceutical Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Ultragenyx Pharmaceutical Inc. is 583.87 and so far today it is 243213.

Performance in the last year for Ultragenyx Pharmaceutical Inc. has been -18.43%. For EPS growth, Ultragenyx Pharmaceutical Inc. has seen a growth of -76.20%, and is looking to grow in the next year to -4.50%. More long term stats show that EPS growth has been *TBA over the last five years and could be 30.00% for the next five years. Ultragenyx Pharmaceutical Inc. has seen sales growth quarter over quarter at *TBA, with EPS growth quarter over quarter at -76.00%. The 20-day simple moving average is -8.38%, with the 200-day simple moving average coming to -3.49%.

Since the IPO date for Ultragenyx Pharmaceutical Inc. on the 1/31/2014, Ultragenyx Pharmaceutical Inc. has seen performance year to date to be -41.01%. With Ultragenyx Pharmaceutical Inc. trading at 63.07, the dividend yield is *TBA, and the EPS is -5.26.

So could Ultragenyx Pharmaceutical Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 151162.91 and the P/B is at 5.82. The P/cash is 6.56, with P/free cash flow at *TBA.

Ultragenyx Pharmaceutical Inc. ability to deal with debt shows that the current ratio is 12.9, and the quick ratio is 12.9. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, Ultragenyx Pharmaceutical Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Ultragenyx Pharmaceutical Inc. is *TBA. Return on assets come to -37.70% with return on investment coming to *TBA.

Insider ownership for Ultragenyx Pharmaceutical Inc., is at 1.90% and institutional ownership comes to 95.10%. Outstanding shares are at 38.83. While shares float is 36.19. The float short is currently 13.21%, and short ratio is 8.19.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Tony Dabbs

Leave a Comment